Home     Print Page  |  Close Window

Investor Overview

Reata is a clinical-stage biopharmaceutical company that develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways involved in the regulation of cellular metabolism and inflammation. Reata’s two most advanced clinical candidates (bardoxolone methyl and omaveloxolone) target the important transcription factor Nrf2 to restore mitochondrial function, reduce oxidative stress, and resolve inflammation.
RETA (Common Stock)
ExchangeNASDAQ (US Dollar)
Change (%) Stock is Up 1.15 (5.06%)
Data as of 04/19/18 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Stock chart for: RETA.O.  Currently trading at $23.87 with a 52 week high of $40.88 and a 52 week low of $19.31.
Data provided by Nasdaq. Minimum 15 minutes delayed.

Investor Contact
Vineet Jindal
Vice President, Strategy
(855) 55-REATA